The study, published in Sports Medicine – Open, was led by Simone Montenegro of the German Sport University Cologne, together with Pamela Wicker, Tim Wiedenmann, Ludwig Rappelt and Lars Donath. The team drew on the Open Powerlifting database, restricting their sample to drug-tested, unequipped “classic” powerlifting competitions sanctioned by the International Powerlifting Federation and its national affiliates between January 2015 and March 2026. To ensure a homogeneous contemporary population, they limited analysis to full-power results comprising the squat, bench press and deadlift, and to athletes aged 21 to 49 years, a window designed to encompass the age of peak competitive performance in the sport, reported at roughly 27 years.

A crucial methodological decision shaped everything that followed. Large athletic databases are noisy: a single athlete may appear dozens of times, and most of those entries capture sub-maximal performances rather than career-best efforts. To solve this, the researchers applied what they call a “Best-Ever” filter. Each unique athlete was linked by name and sex, and only the single competition containing their highest recorded total was retained. Anchoring on the best-total competition, rather than stitching together best lifts from separate events, preserved the internal coherence of the three lifts as one simultaneously achieved performance. The final sample comprised 101,898 athletes, of whom 67,789 were male and 34,109 were female.

The statistical engine of the study was quantile regression, a technique that estimates specific points of the performance distribution, in this case the 50th, 75th, 90th and 99th percentiles, independently, rather than focusing only on the average lifter. Standard errors and confidence intervals were derived through bootstrap resampling to ensure robust inference at the extreme quantiles, and the researchers labeled the four tiers Intermediate, Advanced, Elite and World Class, following terminology common in strength and conditioning practice. The analytical unit was the bodyweight multiplier, the ratio of load lifted to body mass, but the authors were explicit that the ratio served as a diagnostic tool, not a benchmark: the entire point was to test whether a single fixed multiplier could mean the same thing across the body-mass spectrum.

It cannot. The analysis revealed a highly significant, systematic, non-linear decline in relative strength with increasing body mass across all lifts, all percentiles and both sexes. The most striking illustration comes from the male world-class tier: the smoothed 99th-percentile deadlift multiplier fell from 4.37 times bodyweight in the 59-kilogram class to just 2.65 times bodyweight in the 120-plus-kilogram category. In other words, a numerical standard that an elite lightweight could achieve comfortably sits at the absolute frontier of what an elite super-heavyweight can manage. The decay coefficients are small but relentless, and the researchers quantify their meaning precisely: a coefficient of -0.01 means that for every 10 kilograms of additional body mass, an athlete’s expected multiplier drops by exactly 0.1 times, for instance sliding from a 2.1-times to a 2.0-times squat.

Perhaps the most novel finding is that this decline is not uniform across skill levels. Pairwise comparisons of the quantile slopes, conducted with Wald tests for equality of coefficients, confirmed that the rate of relative-strength decay becomes significantly steeper as performance level rises. World-class athletes at the 99th percentile lose relative strength with each kilogram of body mass considerably faster than intermediate lifters at the 50th percentile. The authors suggest a likely explanation rooted in training physiology: muscle hypertrophy follows a linear-log trajectory, so advanced lifters experience diminishing returns in muscle accretion. When elite athletes gain weight, a larger proportion of that new mass may be non-contractile tissue, bone, connective tissue and fat, that inflates the denominator of the strength-to-mass ratio without contributing to the force-producing numerator.

This mechanism connects back to one of biology’s oldest mathematical constraints, the Square-Cube Law. As a body scales up, its mass increases with the cube of its linear dimensions, while the cross-sectional area of muscle, the tissue that actually generates force, increases only with the square. Heavier athletes are therefore structurally constrained to lower strength-to-mass ratios than lighter athletes of equivalent training status, a principle long established in the biomechanics literature. The observed declines in this dataset often exceed the theoretical predictions of pure geometric scaling, and the authors point to the fat-free mass index ceiling as a contributing factor: as lifters approach their natural hypertrophic potential, further mass gain becomes progressively less functional.

The study also documented a systematic shift in what the authors call the internal lift ratio, the percentage contribution of each lift to the competitive total. In the lightest weight classes, the deadlift dominates, contributing roughly 42 to 45 percent of the total. As body mass increases, that dominance erodes: in the heaviest male categories, the gap between deadlift and squat contribution narrows from an eight-percentage-point difference to roughly two points, at approximately 39 versus 37 percent. Regression models indicated that each 10-kilogram increase in body mass is associated with about a 0.44 percentage-point reduction in the deadlift’s share and a 0.28 percentage-point increase in the squat’s share. The likely culprit is soft tissue interference: greater abdominal and thigh girth can compromise the deadlift starting position or lockout, while added body volume may assist the squat through passive joint stability and a reduced effective range of motion.

Sex differences added another layer of complexity. Female athletes exhibited a steeper mass-dependent decline in bench press and squat performance than males. At the 99th percentile, the female squat decay coefficient was -0.0136 against the male -0.0125, meaning that for every 10 kilograms of body mass, a world-class female lifter loses 0.136 times bodyweight in relative squat strength compared with 0.125 for her male counterpart. The female bench press proportion of the total remained essentially static across the mass spectrum. The authors note this upper-body discrepancy may reflect both biological differences in regional muscle distribution and sociological factors, such as lower prior exposure to upper-body training among women, citing meta-analytic evidence that females make larger relative upper-body strength gains in response to training. The practical implication is blunt: applying male-derived multipliers to female athletes sets targets that simply do not correspond to the observed female performance distribution.

To make the findings usable on the gym floor, the researchers converted their statistical models into absolute-load normative atlases, stratified by sex, lift and current IPF weight class, expressed in raw kilograms with no calculation required. A coach can now determine whether an 83-kilogram athlete’s 180-kilogram squat sits at the 50th or the 90th percentile of drug-tested competitors worldwide, and whether the deadlift and bench press sit at comparable percentiles, something no aggregate score like the Wilks or IPF Good Lift coefficient can reveal, since those formulas compress the three lifts into a single number optimized for cross-weight-class ranking. The atlases also offer an empirical anchor for weight-class transitions: because relative multipliers fall even when absolute strength is maintained, an elite athlete moving up a class faces a disproportionately steeper relative decline than an intermediate lifter making the same move. The authors caution that the atlases are current reference values rather than permanent benchmarks, noting that squat and deadlift medians can rise by roughly 2.5 to 7.5 kilograms within five-year periods, and recommend periodic re-derivation. They also acknowledge limitations, including weigh-in manipulation through weight cutting, the absence of anthropometric data such as limb lengths, and the possibility that name-based athlete matching allowed a small number of duplicate records. Still, the message to the strength community is clear: the era of one-size-fits-all bodyweight multipliers is over, and the data have finally caught up with the barbell.

Subject of Research: Percentile-based normative standards for assessing relative and absolute strength across body mass categories in competitive classic powerlifting

Article Title: Percentile-Based Normative Standards for Strength Assessment Beyond Linear Bodyweight Multipliers in Competitive Powerlifters

Article References: Montenegro, S., Wicker, P., Wiedenmann, T., Rappelt, L., & Donath, L. (2026). Percentile-Based Normative Standards for Strength Assessment Beyond Linear Bodyweight Multipliers in Competitive Powerlifters. Sports Medicine – Open, 12(1), Article 136. https://doi.org/10.1186/s40798-026-01111-z

Image Credits: AI Generated

DOI: 10.1186/s40798-026-01111-z

Keywords: powerlifting, bodyweight multipliers, normative standards, quantile regression, relative strength, squat, bench press, deadlift, weight classes, sexual dimorphism, strength and conditioning, IPF

The study, led by researchers including Paul L. Molyneaux, N. A. Hirani and C. C. K. Chia, focuses on a novel therapeutic strategy: delivering a drug directly to the lungs rather than exposing the entire body to high concentrations of medicine. LTI-03 is an inhaled peptide based on the scaffolding domain of caveolin-1, a protein involved in regulating cellular signaling. The compound is being developed to influence pathways that become abnormally activated during pulmonary fibrosis, particularly those governing fibroblast behavior and the excessive production of extracellular matrix.

Fibroblasts are essential repair cells, but in IPF they can become persistently activated and develop into myofibroblasts. These specialized cells produce large quantities of collagen and other structural proteins, laying down scar tissue that thickens the delicate walls of the lung’s air sacs. The resulting architectural changes reduce lung compliance, meaning the lungs become harder to expand, while also disrupting the surface across which oxygen must diffuse. LTI-03 is intended to interrupt this pathological repair response and restore a more balanced cellular environment.

The biological rationale for the treatment is linked to caveolin-1, a membrane-associated protein that helps organize signaling molecules inside cells. Previous research has suggested that reduced caveolin-1 activity may be associated with exaggerated fibrotic responses. Its scaffolding domain can interact with signaling proteins and potentially restrain pathways involved in inflammation, tissue remodeling and fibroblast activation. By using a therapeutic peptide derived from this region, investigators hope to reproduce some of caveolin-1’s regulatory effects without requiring replacement of the entire protein.

In the clinical study, participants received escalating doses of inhaled LTI-03 under a randomized design. Dose-escalation trials are an early but crucial stage in drug development: they are structured primarily to determine whether a treatment can be administered safely, how well it is tolerated, and whether the body is exposed to predictable levels of the compound. Randomization helps reduce the influence of chance and investigator expectations, while the stepwise increase in dose allows researchers to identify any dose-related adverse effects before testing larger populations.

The inhaled route is particularly important for a disease centered in the lungs. A medicine deposited through the airways can potentially reach affected tissue at a higher local concentration while limiting exposure in organs such as the liver, kidneys and heart. This approach may also be valuable for peptide-based drugs, which can be difficult to deliver effectively through traditional tablets. However, inhaled therapies must overcome their own challenges, including deposition in damaged airways, variability in inhaler technique and the possibility of local irritation or bronchial reactions.

The researchers assessed the safety and tolerability of LTI-03 while also examining exploratory signals that could guide future trials. Such signals may include changes in lung function, respiratory symptoms, biological markers of fibrosis and measurements reflecting how the drug behaves in the body after inhalation. In early-stage IPF studies, these secondary observations are not normally sufficient to establish clinical benefit on their own. Their value lies in showing whether the treatment is reaching its intended biological targets and whether a larger, longer study is justified.

Current antifibrotic medicines, including nintedanib and pirfenidone, can slow the decline in lung function for many patients, but they do not eliminate established scar tissue and are not universally tolerated. Gastrointestinal symptoms, liver-related effects and other treatment burdens can limit their use. The search for therapies with different mechanisms is therefore a major priority. LTI-03 represents an attempt to target the cellular signaling network behind fibrosis rather than simply reducing one downstream aspect of disease progression.

The findings do not yet mean that LTI-03 is ready to replace existing treatments or that it can reverse IPF. A dose-escalation study is designed to answer narrower questions than a definitive efficacy trial, and the natural variability of IPF makes it difficult to draw conclusions from small early-stage populations. Larger randomized studies will be needed to determine whether the compound can produce meaningful and durable improvements in forced vital capacity, exercise capacity, symptoms or survival, and whether its safety remains acceptable over prolonged treatment.

Even so, the study adds momentum to a rapidly evolving field in which researchers are moving beyond one-size-fits-all approaches to lung scarring. By combining a biologically targeted peptide with direct pulmonary delivery, LTI-03 seeks to intervene closer to the source of fibrosis while potentially reducing systemic toxicity. The results provide an important early assessment of this strategy and help define the next questions for clinical development: which patients are most likely to respond, how much drug should reach the lungs, and whether modifying caveolin-1-related signaling can change the course of a disease that has long resisted curative treatment.

Subject of Research: Inhaled LTI-03 as an experimental treatment for idiopathic pulmonary fibrosis.

Article Title: Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study.

Article References: Molyneaux, P.L., Hirani, N.A., Chia, C.C.K. et al. Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study. Nat Commun 17, 7620 (2026). https://doi.org/10.1038/s41467-026-75291-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-026-75291-3

Keywords: idiopathic pulmonary fibrosis, LTI-03, inhaled therapy, caveolin-1, pulmonary fibrosis, antifibrotic treatment, lung disease, clinical trial, fibroblasts, regenerative medicine